K. D. Plunket

发表

A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport

S. Kliewer, J. L. Shenk, H. Xu, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines.

Timothy M Willson, L. Moore, T. Willson, 2002, Journal of medicinal chemistry.

A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat.

J. Lehmann, T. Willson, S. Kliewer, 1999, Diabetes.

Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways.

J. Lehmann, S. Kliewer, J. Weiel, 1997, Biochemical pharmacology.

A peroxisome proliferator-activated receptor g ligand inhibits adipocyte differentiation

J. Lehmann, L. Moore, T. Willson, 1999 .

Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα

Millard H. Lambert, Timothy M. Willson, T. Willson, 2002, Nature.

A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity.

J. Auwerx, M. Champy, D. Moras, 2001, Molecular cell.

A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma.

M. Sporn, T. Willson, D. Mangelsdorf, 2000, Molecular endocrinology.

A Synthetic Triterpenoid, 2-Cyano-3,12-dioxooleana-1,9-dien-28-oicAcid(CDDO),IsaLigandforthePeroxisomeProliferator-ActivatedReceptor g

M. Sporn, T. Willson, D. Mangelsdorf, 2000 .

Identification of a chemical tool for the orphan nuclear receptor FXR.

L. Moore, T. Willson, K. Plunket, 2000, Journal of medicinal chemistry.

Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662.

T. Willson, J. L. Shenk, L. Leesnitzer, 2002, Biochemistry.

N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.

J. Lehmann, T. Willson, S. Kliewer, 1998, Journal of medicinal chemistry.

Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors

L. Moore, T. Willson, S. Kliewer, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Effects of fenofibrate on lipid parameters in obese rhesus monkeys.

J. Lehmann, W. Wilkison, S. Kliewer, 2001, Journal of lipid research.

N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.

P. Charifson, K. Brown, S. Blanchard, 1998, Journal of medicinal chemistry.

A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.

J. Lehmann, L. Moore, T. Willson, 1999, Journal of medicinal chemistry.

A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation.

J. Lehmann, L. Moore, T. Willson, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Solid-phase synthesis of hybrid thiazolidinedione-fatty acid PPARγ ligands

T. Willson, S. Blanchard, K. Plunket, 1997 .

Synthesis and biological activity of a novel series of indole-derived PPARγ agonists

Steven G. Blanchard, John A. Ray, Rayomand J. Unwalla, 1999 .

Identification of a series of PPARγ/δ dual agonists via solid-phase parallel synthesis

Millard H. Lambert, Timothy M. Willson, T. Willson, 2001 .

Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight.

T. Willson, M. Lambert, H. Xu, 2001, Bioorganic & medicinal chemistry letters.